Literature DB >> 22938832

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

John Mascarenhas1, Mark L Heaney, Vesna Najfeld, Elizabeth Hexner, Omar Abdel-Wahab, Raajit Rampal, Farhad Ravandi, Bruce Petersen, Gail Roboz, Eric Feldman, Nikolai Podoltsev, Dan Douer, Ross Levine, Martin Tallman, Ronald Hoffman.   

Abstract

Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22938832      PMCID： PMC4114151          DOI： 10.1016/j.leukres.2012.08.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  38 in total

1.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Authors:  Peter J Campbell; Martin Griesshammer; Konstanze Döhner; Hartmut Döhner; Rajko Kusec; Hans C Hasselbalch; Thomas Stauffer Larsen; Niels Pallisgaard; Stéphane Giraudier; Marie-Caroline Le Bousse-Kerdilès; Christophe Desterke; Bernadette Guerton; Brigitte Dupriez; Dominique Bordessoule; Pierre Fenaux; Jean-Jacques Kiladjian; Jean-François Viallard; Jean Brière; Claire N Harrison; Anthony R Green; John T Reilly
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

2.  Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

Authors:  Giovanni Barosi; Dominique Bordessoule; Jean Briere; Francisco Cervantes; Jean-Loup Demory; Brigitte Dupriez; Heinz Gisslinger; Martin Griesshammer; Hans Hasselbalch; Rajko Kusec; Marie-Caroline Le Bousse-Kerdiles; Nicola L Liberato; Monia Marchetti; John T Reilly; Jurgen Thiele
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; Heather Powell; Terra Lasho; Gordon Dewald; Rebecca McClure; Ayalew Tefferi
Journal:  Leuk Res       Date:  2006-03-23       Impact factor: 3.156

4.  Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Authors:  David Dingli; Susan M Schwager; Ruben A Mesa; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

Authors:  Guido Finazzi; Vanesa Caruso; Roberto Marchioli; Giovanni Capnist; Teodoro Chisesi; Carlo Finelli; Luigi Gugliotta; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Raphael Marilus; Carlo Patrono; Enrico Maria Pogliani; Maria Luigia Randi; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  Blood       Date:  2004-12-07       Impact factor: 22.113

Review 7.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

8.  Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.

Authors:  Hongyu Ni; Giovanni Barosi; Damiano Rondelli; Ronald Hoffman
Journal:  Am J Clin Pathol       Date:  2005-06       Impact factor: 2.493

9.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

10.  Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

Authors:  Ruben A Mesa; Chin-Yang Li; Rhett P Ketterling; Georgene S Schroeder; Ryan A Knudson; Ayalew Tefferi
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113
View more
  14 in total

1.  Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors:  Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-12-26

2.  How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Authors:  G Barosi; R P Gale
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

3.  Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Authors:  X Cahu; P Chevallier; A Clavert; F Suarez; M Michallet; L Vincent; S Vigouroux; D Blaise; C Mariette; K Bilger; M Robin; I Yakoub-Agha; R Peffault de Latour; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

Review 4.  Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.

Authors:  Michael Tallarico; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

5.  Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Authors:  Talha Badar; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Jorge E Cortes; Naveen Pemmaraju; Sherry R Pierce; Kate J Newberry; Naval Daver; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-06-11       Impact factor: 3.156

Review 6.  Genomics of MPN progression.

Authors:  Anand A Patel; Olatoyosi Odenike
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

Review 8.  Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.

Authors:  Mark L Heaney; Gabriela Soriano
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

9.  Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

Authors:  John O Mascarenhas; Raajit K Rampal; Heidi E Kosiorek; Rupali Bhave; Elizabeth Hexner; Eunice S Wang; Aaron Gerds; Camille N Abboud; Marina Kremyanskaya; Dimitry Berenzon; Olatoyosi Odenike; Noushin Farnoud; Aishwarya Krishnan; Rona Singer Weinberg; Erin McGovern; Mohamed E Salama; Vesna Najfeld; Juan S Medina-Martinez; Juan E Arango Ossa; Max F Levine; Yangyu Zhou; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Ronald Hoffman
Journal:  Blood Adv       Date:  2020-10-27

Review 10.  Accelerated Phase of Myeloproliferative Neoplasms.

Authors:  Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal:  Acta Haematol       Date:  2021-04-21       Impact factor: 2.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.